Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Bristol-Myers Squibb (NYSE: BMY) and increased the price target from $75 to $82. This adjustment reflects a positive outlook on the company's performance.